Loading quotes...
Forecast
There is no analyst data available for this company.
Discussions in the community
- EuropÀische Aktien
u user_ce10af IV in Schnack
0 13 - 0 21
News Go to news feed
Coloplast A-S announces quarterly results for 03.11.2026
Coloplast A-S will release results on 03.11.2026 for the quarter ended 30.09.2026. Eleven analysts on average estimate EPS for the quarter at 5.91 DKK versus 3.88 DKK a year earlier, and 15 analysts forecast revenue of 7.40 bn DKK versus 6.96 bn DKK in the year-ago quarter. For the most recently completed fiscal year, 22 analysts predict EPS of 25.45 DKK (prev. year 16.13 DKK) and 23 analysts expect annual revenue of 28.88 bn DKK (prev. year 27.87 bn DKK). » More on finanzen.net
Coloplast A-S expects slight revenue growth and higher EPS for Q3, results on Nov. 3
Coloplast A-S will release results for the quarter ended Sept. 30 on Nov. 3. Ten analysts see an average EPS of USD 0.090 versus USD 0.060 a year earlier. Quarterly revenues are forecast on average at USD 1.12 billion (+2.6% year-on-year). For the past fiscal year analysts on average expect EPS of USD 0.385 and revenue of USD 4.38 billion. » More on finanzen.net
Coloplast share falls after downgrade by JPMorgan
Coloplastâs share dropped 3.3% and fell intraday to as low as 427.8 DKK after JPMorgan cut its rating from "Neutral" to "Underweight" and lowered the December 2027 price target from 484 DKK to 377 DKK (about â22%). The bank cited a high P/E ratio of 35.35 and a valuation premium of roughly 20% versus the medtech sector, while earnings growth lags the industry. JPMorgan also noted governance uncertainty and expects the new CEO is likely to revise midâterm financial targets down when results are presented on 3 November; weak Q3 margins and increased short interest add further pressure. » More on de.investing.com
Coloplast A-S (B) announces quarterly results for period to 30 June 2026
Coloplast A-S (B) will present the numbers for the quarter to 30 June 2026 on 18 August 2026. Ten analysts expect on average an EPS of 6.08 DKK versus 3.57 DKK in the prior year. Fourteen analysts forecast revenue of on average 7.26 billion DKK, an increase of 4.34% versus the year-earlier quarter. For the current fiscal year, consensus estimates are 24.88 DKK earnings per share and 28.79 billion DKK revenue. » More on finanzen.net
Coloplast A-S (spons ADRs) announces quarterly results for June 30, 2026
Coloplast A-S (spons ADRs) will present results for the quarter ended June 30, 2026 on August 18, 2026. Nine analysts expect EPS of on average $0.093 (prior year $0.050); 13 analysts forecast revenue of about $1.11 billion (up 5.4% from $1.06 billion). For the current fiscal year, consensus estimates are $0.382 EPS and $4.43 billion in revenue (prior year: $0.240 / $4.12 billion). » More on finanzen.net
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 7.44bn | 105.80% |
| Gross profit | 4.87bn | 24.73% |
| Net profit | 1.18bn | 35.56% |
| EBITDA | 2.1bn | 106.10% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | âŹ14.88bn |
Number of shares | 225.37m |
52-week high/low | âŹ86.62 - âŹ49.48 |
Dividend yield | 4.73% |
Dividends TTM | âŹ3.08 |
Beta | 0.55 |
P/E ratio | 36.08 |
PEG ratio | -2.34 |
P/B ratio | 7.76 |
P/S ratio | 3.83 |
Company profile
Coloplast A/S develops, manufactures, and markets medical products. The company is engaged in the development, marketing and sale of intimate healthcare products and services, targeting people with diseases of private and personal nature. Its operations are structured into four business areas: Ostomy Care offering products for people whose intestinal outlet has been rerouted through the abdominal wall, Continence Care products for people suffering from diseases of and damage to the urinary system, Urology Care products for people suffering from diseases of and damage to the kidneys, the urinary system or the male reproductive system and Wound & Skin Care for the treatment of chronic wounds and skin care products for prevention and treatment. The firm supplies products to hospitals, institutions as well as wholesalers and pharmacies.
| Name | COLOPLAST |
| CEO | Gavin Wood |
| Headquarters | HumlebĂŠk,
ze Denmark |
| Website | |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| IPO | 24/01/2007 |
| Employees | 17,524 |
Ticker symbols
| Exchange | Symbol |
|---|---|
XETRA | CBHD.DE |
Pnk | CLPBF |
Nasdaq Copenhagen | COLO-B.CO |
Copenhagen | COLO B.CO |
Frankfurt | CBHD.F |
DĂŒsseldorf | CBHD.DU |
London | 0QBO.L |
SIX | COLOB.SW |
MĂŒnchen | CBHD.MU |
Wien | COLO.VI |